Exelixis The Courier / May 3, 2021
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
Exelixis News
The Courier
Exelixis Jumbo News / May 3, 2021
The recent report with the title Global mTOR Inhibitors Market Research Report 2021-2027 from Market Research Place covers a descriptive analysis with detailed segmentation, complete research and development history, latest news. The report contains a detailed and deep understanding of the market which can be used to harness high profits from the businesses.
Exelixis SoccerNurds / May 2, 2021
The Rhabdomyosarcoma Drug Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
Exelixis SoccerNurds / May 2, 2021
The Wilms' Tumor Treatment Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
Exelixis SoccerNurds / May 2, 2021
The Proto-Oncogene Drgu Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
Exelixis Equities.com / May 1, 2021
Exelixis Inc (NASDAQ: EXEL) shares fell -0.28% to end trading Friday at $24.62 per share - a net change of $-0.07. Shares traded between $25.04 and $24.49 throughout the day. 1408007 shares of Exelixis Inc exchanged hands. Visit Exelixis Inc's profile for more information.
Exelixis Inc (EXEL) falls 0.28% for April 30
Equities.com
Exelixis SoccerNurds / May 1, 2021
The Ureter Cancer Drugs Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
Exelixis SoccerNurds / May 1, 2021
Ureter Cancer Drugs Market analysis Ureter Cancer Drugs Market forecast Ureter Cancer Drugs Market Growth Ureter Cancer Drugs Market size Ureter Cancer Drugs Market trends
Ureter Cancer Drugs Market Growth – SoccerNurds
SoccerNurds
Exelixis MarketBeat / Apr 30, 2021
Exelixis, Inc. (NASDAQ:EXEL) - Oppenheimer boosted their Q2 2021 EPS estimates for Exelixis in a report released on Wednesday, April 28th. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will post earnings per share of $0.12 for the quarter, up from their prior forecas
MarketBeat
Exelixis GuruFocus.com / Apr 30, 2021
For the details of EULAV Asset Management's stock buys and sells,go to https://www.gurufocus.com/guru/eulav+asset+management/current-portfolio/portfolio These are the top 5 holdings of EULAV Asset Management Teledyne Technologies Inc (TDY) - 241,300 shares, 2.67% of the total portfolio. Ansys Inc (ANSS) - 215,029 shares, 1.96% of the total portfolio.
EULAV Asset Management Buys Ve
GuruFocus.com
Exelixis The Courier / Apr 30, 2021
Adrenal cancers (carcinomas) are very rare, and the exact number diagnosed in the United States each year is not known. It is probably around 200 per year. These cancers are much less common than benign adrenal tumors (adenomas), which are found fairly often among middle aged and elderly people.
Exelixis Valley Bugler Newspaper / Apr 30, 2021
A recently launched research document entitled Global Cabozantinib Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 contains a brief analysis of the basic details of the market valuation, industry expansion, and market growth opportunities that influence market growth. The report researches the global Cabozantinib market to evaluate its current and future potential.
Valley Bugler Newspaper
Exelixis Equities.com / Apr 30, 2021
Exelixis Inc (NASDAQ: EXEL) shares fell -0.24% to end trading Thursday at $24.69 per share - a net change of $-0.06. Shares traded between $24.88 and $24.47 throughout the day. 657900 shares of Exelixis Inc exchanged hands. Visit Exelixis Inc's profile for more information.
Exelixis Inc (EXEL) falls 0.24% for April 29
Equities.com
Exelixis KSU | The Sentinel Newspaper / Apr 30, 2021
Latest research on Global included a special section on the Cancer Drug Therapy Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million).
Exelixis Valley Bugler Newspaper / Apr 30, 2021
The market report, entitled Global Medicine for the Treatment of Advanced Thyroid Cancer Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 features extensive research based on this market which inspects the intensive structure of the present market along with historical analysis.
Exelixis GuruFocus.com / Apr 30, 2021
For the details of Lipe & Dalton's stock buys and sells,go to https://www.gurufocus.com/guru/lipe+%26+dalton/current-portfolio/portfolio These are the top 5 holdings of Lipe & Dalton Apple Inc (AAPL) - 89,198 shares, 6.05% of the total portfolio. Shares reduced by 5.48% United Rentals Inc (URI) - 23,153 shares, 4.23% of the total portfolio.
GuruFocus.com
Exelixis Pharmacy Times / Apr 30, 2021
Anti-vascular endothelial growth factor (VEGF) therapy is used to treat a wide variety of malignancies, in the front-line setting and beyond. 4 Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals Inc) was the first VEGF tyrosine kinase inhibitor (TKI), approved in 2005 for the treatment of advanced renal cell carcinoma.
Exelixis MarketBeat / Apr 29, 2021
Exelixis (NASDAQ:EXEL) is set to announce its earnings results after the market closes on Thursday, May 6th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Exelixis The Courier / Apr 29, 2021
Home / Business /Global C-MET & HGF Inhibitors Market Survey 2021 - Exelixis, Daiichi Sankyo, Novartis, Ipsen, Merck, Pfizer Global C-MET & HGF Inhibitors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Executive Summary: MarketQuest.biz has announced a business intelligence study on Global C-MET & HGF Inhibitors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 that reveals diverse information allowing keen market participants to understand the measures of the market.
Exelixis KSU | The Sentinel Newspaper / Apr 29, 2021
HNY Research has announced the Latest edition of " Kidney Cancer Drugs Market Report 2021 Opportunities, Challenges, Strategies and Forecasts 2027". This report provides in-depth analysis of market statistic, market size, market growth, by product type, industry application, market trends and Covid-19 Impact on Global and Regional Market.
KSU | The Sentinel Newspaper